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Abstract
Medicinal application of many complex natural products is precluded by the impracticality of their
chemical synthesis. Pactamycin, the most structurally-intricate aminocyclopentitol antibiotic,
displays potent anti-prolific properties across multiple phylogenetic domains, but is highly
cytotoxic. A limited number of analogs produced by genetic engineering technologies show
reduced cytotoxicity against mammalian cells, renewing promise for therapeutic applications. For
decades, an efficient synthesis of pactamycin amenable to analog derivatizations has eluded
researchers. Herein, we present a short asymmetric total synthesis of pactamycin. An
enantioselective Mannich reaction/symmetry-breaking reduction sequence was designed to enable
assembly of the entire carbon core skeleton in under five steps and control critical three-
dimensional (stereochemical) functional group relationships. This modular route totals fifteen
steps and is immediately amenable for structural analog synthesis.
Complex organic molecules produced by bacteria have been relied upon for the treatment of
numerous disease types for nearly a century (1–4); however, many naturally-derived
compounds that exhibit interesting bioactivities are practically inaccessible via synthetic
organic chemistry. A natural product’s structural complexity can create an insurmountable
impediment to the preparation of analogs that might exhibit improved characteristics. An
ongoing challenge in the field of synthetic chemistry is the development of methods that
close the gap between the efficiency of biosynthetic machinery and laboratory synthesis.
Because of the inherent flexibility of the latter, success in this endeavor could provide access
to useful structural variants that might otherwise be inaccessible.
Pactamycin (1, Fig. 1) was isolated from Streptomyces pactum var pactum in 1961 by
researchers at the Upjohn Company (5). The bioactivity profile of this natural product is
remarkable as it displays antitumor, antimicrobial, antiviral, and antiprotozoal properties by
acting as a universal inhibitor of translocation (6–9). Within the ribosomal subunit in which
it interacts, pactamycin mimics an RNA dinucleotide through interactions of its aniline and
salicylate moieties with stem loops in the 16S RNA (10). Unfortunately, therapeutic benefits
have yet to be realized due to high cytotoxicity (IC50 95 nM against human diploid
embryonic cell line MRC-5) (11). Pactamycin is a prototypical example of a promising
bioactive natural product whose complexity hampers investigation of structure/activity
relationships (SAR) that might lead to a serviceable therapeutic application and/or better
understanding of intrinsic bioactivity.
Genetic engineering studies have reignited promise for medicinal application as 7-deoxy-
and 8″-hydroxy-derivatives were isolated and displayed diminished cytotoxity (11–14). In
the context of the work described herein, it is worth noting that Lu et al. contend that the
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structural complexity of 1 renders these and related structural modifications “inaccessible by
synthetic organic chemistry” (12). Conversely, we have proceeded from the hypothesis that
the genetic engineering approach to pactamycin analogs might be inherently limited by the
biosynthetic machinery (15). While pactamycin is commercially available, a chemical
approach to its synthesis could in principle provide far greater opportunity and flexibility for
discovering and advancing useful compounds; however, this tactic will only be feasible in
the presence of an efficient synthesis platform that rapidly develops the level of structural
complexity that is present. In fact, synthetic interest in pactamycin has recently flourished,
culminating in the landmark 32-step total synthesis from Hanessian and coworkers (16, 17),
as well as numerous partial synthetic studies (18–22). Despite these creative, state-of-the-art
approaches, a compelling case can be made that a more practical synthesis solution is
needed.
In this report, we disclose a fifteen-step total synthesis of pactamycin which can
immediately produce the natural product on milligram scale and a key branch point
intermediate on gram scale. Emphasis was placed on both modular construction and
introduction of functionality in its final desired form, enabling an approach amenable to
derivatization for analog synthesis. Late-stage introduction of the aniline and salicylate
binding elements provides an opportunity for future SAR studies.
Critical to our synthetic plan was the recognition of a hidden symmetry in the northeast
quadrant of pactamycin (1). Depicted in Fig. 2A, the carbon chain connecting C4 and C8
can be extracted to a symmetrical α-ureido-2,4-pentanedione 2. We envisaged simplified
formation of the fully-substituted C1 center via a Mannich reaction. Due to the symmetrical
methyl ketone substituents at C1, diastereoselectivity considerations are obviated, allowing
for a focus on the enantioselective C2-amino incorporation during the C1–C2 bond
construction. The nascent C2 stereocenter would then need to direct a site- and
diastereoselective diketone mono-reduction, setting the C2/C1/C7 stereotriad (red arrows,
Fig. 2B). This sequence would provide the entire pactamycin carbon core skeleton from
which modular delivery of various functionality (Fig. 2C) could provide 1 and/or its
congeners in rapid fashion.
The first challenge we faced was implementation of the Mannich reaction with an
appropriately configured imine electrophile. We were encouraged by results reported by
Schaus and coworkers wherein cinchona alkaloids were effective in catalyzing the
enantioselective addition of simple 1,3-dicarbonyls to acyl imines (23, 24); however, the
required asymmetric Mannich addition of α-amino-substituted dicarbonyls was heretofore
unknown. Additionally, with our goal of modular construction in mind, we planned to install
the unusual 1,1-dimethylurea in its native form early in our route, a tactic that was expected
to obviate protection/deprotection/acylation steps that characterize all other pactamycin
synthetic studies.
Pronucleophile 2 was synthesized in two steps (25) from commodity chemical acetylacetone
(2.5 kg ~ $75) and subjected to adapted Mannich conditions with cinnamaldehyde-derived
imine 3 (Fig. 3). An evaluation of Lewis bases led to selection of cinchonidine (7) as the
catalyst of choice, providing Mannich product 4 in 70% isolated yield and 97:3 enantiomeric
ratio (94% yield, 84:16 er before removal of the racemate by trituration). An X-ray
diffraction study of a derivative (25) revealed formation of the illustrated (R) configuration
at C2. The reader will note that this nominally corresponds to the incorrect configuration at
C2, but the advancement of this stereochemical mistake was in fact critical to orchestrate
downstream stereochemical outcomes and efficiently complete the synthesis (vide infra).
The strategic selection of cinnamyl imine 3 as the Mannich electrophile translated to the
installation all five carbons of the pactamycin core, with appropriate functional handles, in
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this initial C–C bond construction. This reaction constitutes a useful advance in the synthesis
of differentiated, highly functionalized 1,2-diamines by adaptation of the Schaus conditions
to a new nucleophile/electrophile pair; extension to other urea/carbamate combinations can
be envisaged.
The proposed desymmetrization of the Mannich adduct (4 → 5) is complicated by the fact
that four diastereomeric mono-reduction products are possible. Lithium tri(tert-
butoxy)aluminum hydride (LTBA) emerged as a superior reducing agent for the
desymmetrization, affording hydroxyketone 5 with high diastereoselectivity (>10:1 ratio of
5:Σ(other diastereomers)) in 72% yield. This reduction delivered the illustrated (1R,2R,7S)-
product; therefore, the incorrect C2 isomer was parlayed into the correct C1/C7
configurations. Subsequent silyl protection of the C7 hydroxyl gave methyl ketone 6.
Our attention then shifted to installation of the C4 side-chain and cyclization to complete the
cyclopentenone core (Fig. 4). The lithium enolate of ketone 6 was treated with formaldehyde
gas (generated in situ by the pyrolysis of paraformaldehyde) resulting in the single aldol
addition product 8 (26, 27). Alkene ozonolysis furnished aldehyde 9 poised for
intramolecular aldol condensation. Cyclization of the β-hydroxy ketone (28) was effected
upon treatment with sodium methoxide to provide the five-membered pactamycin core
structure (10) in 50% yield over two steps. Under the basic reaction conditions, the
configurationally labile C2 stereocenter was inverted and only the correct C2 isomer was
observed in the product enone 10. This serendipitous event corrected our initial
stereochemical error, simplifying subsequent core manipulation.
With cyclopentenone 10 in hand, three challenges remained: (i) C5 methide addition, (ii) C4
hydroxylation, and (iii) C3 aniline installation. An epoxidation/nucleophilic aniline ring-
opening sequence was pursued for access to the trans-anilinoalcohol, inspired by a related
approach by Hanessian and coworkers (16, 17). We anticipated subsequent nucleophilic
methylation of the C5 ketone would complete the core functionalization. As we explored
this proposed route, we discovered the importance of both the order of these steps and the
protecting group identity at the C4 hydroxymethylene.
Nucleophilic epoxidation of enone 10 with basic hydrogen peroxide provided epoxy alcohol
11 with high diastereoselectivity. The sterically demanding TBDPS protecting group was
imperative to ensure diastereoselective addition in the subsequent C5 methylation and to
withstand the aniline epoxide-opening conditions. Installation of the silyl group provided
ketone 12, which was then treated with methyl Grignard to provide carbinol 13, gratifyingly
from the required concave facial trajectory. Nucleophile approach from the convex surface
of analogous oxobicyclo[3.1.0]hexane systems is well documented (16, 17, 29) and would
have provided the wrong stereochemical outcome. In the present case, we surmise that this
innate preference is overridden at least in part via direction by the urea functionality, lending
additional support to the strategic decision to incorporate this functionality in its native form
from the outset. Epoxide 12 is the crucial branch point for analogue synthesis and has been
reached in gram-quantity on a single pass. The epoxide was subjected to a Sc(OTf)3-
promoted nucleophilic ring-opening with 3-acetylaniline (17), proceeding in 66% yield with
18% recovery of the starting material to install the C3 aniline derivative. The addition of this
anilino functionality in its desired, unprotected form completed functionalization of the
pactamycin core (14).
Deprotection of both silyl ethers was accomplished upon treatment with TBAF to provide
tractable tetraol 15 in 90% yield, leaving a highly reactive primary alcohol for selective
acylation. A ketene-mediated acylation protocol developed by Delgado (30) and exploited
by Hanessian (16, 17) proved effective in completing the sterically encumbered acylation
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and providing penultimate intermediate 16. Carboxybenzyl deprotection occurred rapidly
under hydrogenolysis conditions using Pearlman’s catalyst (31) in 82% yield. This
deprotection completed the synthesis of pactamycin in fifteen steps and 1.9% overall yield.
The route is flexible and should be amenable to the preparation of congeners since the
introduction of highly-functionalized side chains in unprotected form (urea, salicylate, meta-
acetyl aniline) has been demonstrated.
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Structure of pactamycin (1).
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(A) Hidden symmetry recognition within pactamycin core. Blue dots highlight a 5-carbon
chain from which to begin the synthesis. (B) Red arrows illustrate the pivotal Mannich
addition and symmetry-breaking reduction steps. (C) Proposed modular construction of
pactamycin. Colored components may be varied and introduced for analogue synthesis and
SAR studies.
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Mannich reaction and diastereoselective diketone monoreduction. This two-step sequence
installs all pactamycin core carbons as well as three contiguous stereocenters. Reagents and
conditions are as follows. (a) Catalyst 7 (20 mol %), dichloromethane (CH2Cl2), −65 °C; (b)
lithium tri(tert-butoxy)aluminum hydride (LTBA), tetrahydrofuran (THF), −40 °C; (c) tert-
butyldimethysilyl trifluromethanesulfonate (TBSOTf), 2,6-lutidine, CH2Cl2, −78 °C.
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Elaboration of 6 to pactamycin (1) via modular incorporation of unprotected functionality.
Reagents and conditions are as follows. (a) lithium diisopropylamide (LDA), formaldehyde
(CH2O(g)), THF, −78 to −45 °C; (b) ozone (O3), CH2Cl2, −78 °C, then dimethylsulfide
(Me2S), −78 °C to room temperature (rt); (c) sodium methoxide (NaOMe), THF, 0 °C; (d)
hydrogen peroxide (H2O2), sodium hydroxide (NaOH), 7:1 CH2Cl2:methanol (MeOH), 0
°C; (e) chloro(tert-butyl)diphenylsilane (TBDPSCl), triethylamine (NEt3),
dimethylaminopyridine (DMAP) (10 mol %), CH2Cl2, 0 °C to rt; (f) methylmagnesium
bromide (MeMgBr), THF, 0 °C; (g) 3-acetylaniline (17), scandium(III)
trifluoromethanesulfonate (Sc(OTf)3), toluene, 60 °C; (h) tetrabutylammonium fluoride
(TBAF), THF, 0 °C; (i) potassium carbonate (K2CO3), 18, dimethylacetamide (DMA); (j)
palladium hydroxide on carbon (Pd(OH)2/C), hydrogen (H2) (1 atm), MeOH.
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